The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Leadership - Agios; Astellas Pharma; Genentech; PTC Therapeutics; Syros Pharmaceuticals
Stock and Other Ownership Interests - Auron Therapeutics
Consulting or Advisory Role - Abbvie; Agios; Amgen; Astellas Pharma; BioTheryX; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Daiichi Sankyo Pharmaceutical; Foghorn Therapeutics; Genentech; Gilead Sciences; Janssen; Jazz Pharmaceuticals; Novartis; PinotBio; Seagen; Syndax
Research Funding - Bayer; Syndax
A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
 
Jan Philipp Bewersdorf
No Relationships to Disclose
 
Srdan Verstovsek
Consulting or Advisory Role - Celgene; Constellation Pharmaceuticals; Incyte; Novartis; Sierra Oncology
Research Funding - AbbVie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Galecto (Inst); Geron (Inst); Incyte (Inst); Kartos Therapeutics (Inst); PharmaEssentia (Inst); Protagonist Therapeutics (Inst); Sierra Oncology (Inst); Telios (Inst)
 
Andriy Derkach
No Relationships to Disclose
 
Lucia Masarova
No Relationships to Disclose
 
Naveen Pemmaraju
Employment - MD Anderson Cancer Center
Leadership - ASCO; ASH
Consulting or Advisory Role - Abbvie; Aplastic Anemia and MDS International Foundation; Aptitude Health; Astellas Pharma; Blueprint Medicines; Bristol Myers Squibb; CancerNet; CareDx; Celgene; Cimeio Therapeutics; Clearview Healthcare Partners; CTI BioPharma Corp; Curio Science; Dava Oncology; EUSA Pharma; Harborside Press; Imedex; Immunogen; Intellisphere; Intellisphere; Magdalen Medical Publishing; Medscape; Menarini Group; Neopharm; Novartis; OncLive; Pacylex; Patient Power; Peerview; Pharmaessentia; Physicans' Education Resource
Research Funding - US DOD (Inst)
Other Relationship - Karger Publishers
(OPTIONAL) Uncompensated Relationships - Dan's House of Hope; Oncology Times
 
Eytan M. Stein
No Relationships to Disclose
 
Michael J. Mauro
Honoraria - Abbvie; Bristol-Myers Squibb; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Novartis; Pfizer; Takeda
Research Funding - Abbvie; Bristol-Myers Squibb; Novartis; Pfizer; Sun Pharma
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Novartis; Pfizer; Takeda
 
Raajit Rampal
Honoraria - Protagonist Therapeutics
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Constellation Pharmaceuticals; CTI BioPharma Corp; Disc Medicine; Galecto; Incyte; Karyopharm Therapeutics; Novartis; Pharmaessentia; Promedior; SERVIER; Sierra Oncology; Stemline Therapeutics; Sunimoto Dainippon; Zentalis
Research Funding - Constellation Pharmaceuticals; Ryvu Therapeutics; Stemline Therapeutics; Zentalis
Travel, Accommodations, Expenses - Incyte; Sierra Oncology
 
Prithviraj Bose
Honoraria - Abbvie; Blueprint Medicines; BMS; CTI BioPharma Corp; Incyte; Karyopharm Therapeutics; Novartis; Pharmaessentia
Consulting or Advisory Role - Sierra Oncology
Research Funding - Blueprint Medicines (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Cogent Biosciences (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Incyte (Inst); Kartos Therapeutics (Inst); NS Pharma (Inst); Promedior (Inst)